-
Something wrong with this record ?
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update
A. Masson-Lecomte, A. Birtle, B. Pradere, O. Capoun, E. Compérat, JL. Domínguez-Escrig, F. Liedberg, L. Makaroff, P. Mariappan, M. Moschini, BP. Rai, BWG. van Rhijn, SF. Shariat, EJ. Smith, JYC. Teoh, V. Soukup, R. Wood, EN. Xylinas, F. Soria, T....
Language English Country Switzerland
Document type Journal Article, Practice Guideline
- MeSH
- Carcinoma, Transitional Cell * therapy diagnosis MeSH
- Humans MeSH
- Kidney Neoplasms * therapy diagnosis MeSH
- Ureteral Neoplasms * therapy diagnosis MeSH
- Societies, Medical MeSH
- Urology standards MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Practice Guideline MeSH
- Geographicals
- Europe MeSH
BACKGROUND AND OBJECTIVE: We present a summary of the 2025 update for the European Association of Urology (EAU) guidelines for upper urinary tract urothelial carcinoma (UTUC). The aim is to provide practical recommendations on the clinical management of UTUC with a focus on diagnosis, treatment, and follow-up. METHODS: For the 2025 guidelines on UTUC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with UTUC. The guidelines stress the importance of appropriate treatment taking into account patient values and preferences. Key updates in the 2025 UTUC guidelines include: significant changes to the recommendations for UTUC diagnosis; complete revision of the sections addressing risk stratification, ureteroscopy, and the surgical approach for radical nephroureterectomy; addition of four new recommendations, two related to kidney-sparing management of localised low-risk UTUC and a further two related to management of high-risk nonmetastatic UTUC; a review and adaptation of recommendation for UTUC follow-up; and addition of a new section addressing quality indicators for UTUC management. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2025 EAU guidelines on UTUC offers valuable insights into risk factors, diagnosis, classification, treatment, and follow-up for UTUC. The guidelines contain information on the management of individual patients according to the current best evidence and are designed for effective integration in clinical practice.
Department of Pathology Medical University of Vienna Vienna Austria
Department of Urology Bichat Claude Bernard Hospital AP HP Université de Paris Paris France
Department of Urology Fundación Instituto Valenciano de Oncología Valencia Spain
Department of Urology Pitie Salpetriere Hospital AP HP Paris France
Department of Urology Skåne University Hospital Malmö Sweden
Department of Urology St Louis Hospital AP HP Université de Paris Paris France
Department of Urology UROSUD La Croix Du Sud Hospital Quint Fonsegrives France
Edinburgh Bladder Cancer Surgery University of Edinburgh Western General Hospital Edinburgh UK
Fight Bladder Cancer Chinnor UK
GRC 5 Predictive Onco Uro Sorbonne University Paris France
Guidelines Office European Association of Urology Arnhem The Netherlands
Institution of Translational Medicine Lund University Malmö Sweden
Patient representative European Association of Urology Arnhem The Netherlands
Rosemere Cancer Centre Lancashire Teaching Hospitals NHS Foundation Trust Preston UK
University of Central Lancashire Preston UK
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015524
- 003
- CZ-PrNML
- 005
- 20250731091039.0
- 007
- ta
- 008
- 250708s2025 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.eururo.2025.02.023 $2 doi
- 035 __
- $a (PubMed)40118741
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Masson-Lecomte, Alexandra $u Department of Urology, St. Louis Hospital, AP-HP, Université de Paris, Paris, France. Electronic address: alexandra.massonlecomte@aphp.fr
- 245 10
- $a European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: Summary of the 2025 Update / $c A. Masson-Lecomte, A. Birtle, B. Pradere, O. Capoun, E. Compérat, JL. Domínguez-Escrig, F. Liedberg, L. Makaroff, P. Mariappan, M. Moschini, BP. Rai, BWG. van Rhijn, SF. Shariat, EJ. Smith, JYC. Teoh, V. Soukup, R. Wood, EN. Xylinas, F. Soria, T. Seisen, P. Gontero
- 520 9_
- $a BACKGROUND AND OBJECTIVE: We present a summary of the 2025 update for the European Association of Urology (EAU) guidelines for upper urinary tract urothelial carcinoma (UTUC). The aim is to provide practical recommendations on the clinical management of UTUC with a focus on diagnosis, treatment, and follow-up. METHODS: For the 2025 guidelines on UTUC, new and relevant evidence was identified, collated, and appraised via a structured assessment of the literature. Databases searched included Medline, EMBASE, and the Cochrane Libraries. Recommendations within the guidelines were developed by the panel to prioritise clinically important care decisions. The strength of each recommendation was determined according to a balance between desirable and undesirable consequences of alternative management strategies, the quality of the evidence (including the certainty of estimates), and the nature and variability of patient values and preferences. KEY FINDINGS AND LIMITATIONS: Key recommendations emphasise the importance of thorough diagnosis, treatment, and follow-up for patients with UTUC. The guidelines stress the importance of appropriate treatment taking into account patient values and preferences. Key updates in the 2025 UTUC guidelines include: significant changes to the recommendations for UTUC diagnosis; complete revision of the sections addressing risk stratification, ureteroscopy, and the surgical approach for radical nephroureterectomy; addition of four new recommendations, two related to kidney-sparing management of localised low-risk UTUC and a further two related to management of high-risk nonmetastatic UTUC; a review and adaptation of recommendation for UTUC follow-up; and addition of a new section addressing quality indicators for UTUC management. CONCLUSIONS AND CLINICAL IMPLICATIONS: This overview of the 2025 EAU guidelines on UTUC offers valuable insights into risk factors, diagnosis, classification, treatment, and follow-up for UTUC. The guidelines contain information on the management of individual patients according to the current best evidence and are designed for effective integration in clinical practice.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a karcinom z přechodných buněk $x terapie $x diagnóza $7 D002295
- 650 12
- $a nádory ledvin $x terapie $x diagnóza $7 D007680
- 650 _2
- $a společnosti lékařské $7 D012955
- 650 12
- $a nádory močovodu $x terapie $x diagnóza $7 D014516
- 650 _2
- $a urologie $x normy $7 D014572
- 651 _2
- $a Evropa $7 D005060
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 700 1_
- $a Birtle, Alison $u Rosemere Cancer Centre, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK; University of Manchester, Manchester, UK; University of Central Lancashire, Preston, UK
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France
- 700 1_
- $a Capoun, Otakar $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia
- 700 1_
- $a Compérat, Eva $u Department of Pathology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Domínguez-Escrig, José L $u Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain
- 700 1_
- $a Liedberg, Fredrik $u Institution of Translational Medicine, Lund University, Malmö, Sweden; Department of Urology, Skåne University Hospital, Malmö, Sweden
- 700 1_
- $a Makaroff, Lydia $u Fight Bladder Cancer, Chinnor, UK; World Bladder Cancer Patient Coalition, Brussels, Belgium
- 700 1_
- $a Mariappan, Paramananthan $u Edinburgh Bladder Cancer Surgery, University of Edinburgh, Western General Hospital, Edinburgh, UK
- 700 1_
- $a Moschini, Marco $u Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
- 700 1_
- $a Rai, Bhavan P $u Department of Urology, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- 700 1_
- $a van Rhijn, Bas W G $u Department of Surgical Oncology (Urology), Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Smith, Emma J $u Guidelines Office, European Association of Urology, Arnhem, The Netherlands
- 700 1_
- $a Teoh, Jeremy Y C $u S.H. Ho Urology Centre, Department of Surgery, Faculty of Medicine, Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Soukup, Viktor $u Department of Urology, General University Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czechia
- 700 1_
- $a Wood, Robert $u Patient representative, European Association of Urology, Arnhem, The Netherlands
- 700 1_
- $a Xylinas, Evanguelos N $u Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris, Paris, France
- 700 1_
- $a Soria, Francesco $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 700 1_
- $a Seisen, Thomas $u GRC 5 Predictive Onco-Uro, Sorbonne University, Paris, France; Department of Urology, Pitie-Salpetriere Hospital, AP-HP, Paris, France
- 700 1_
- $a Gontero, Paolo $u Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy
- 773 0_
- $w MED00001669 $t European urology $x 1873-7560 $g Roč. 87, č. 6 (2025), s. 697-716
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40118741 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091033 $b ABA008
- 999 __
- $a ok $b bmc $g 2366395 $s 1252649
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 87 $c 6 $d 697-716 $e 20250320 $i 1873-7560 $m European urology $n Eur Urol $x MED00001669
- LZP __
- $a Pubmed-20250708
